Revenue Potential: Apitegromab has a total revenue potential of greater than $1 billion. Scholar Rock Holding Corp ...

Scholar Rock Holding (SRRK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Etzer Darout from BMO Capital reiterated a Buy rating on the ...

H.C. Wainwright raised the firm’s price target on Scholar Rock (SRRK) to $40 from $35 and keeps a Buy rating on the shares. Scholar Rock ...

Scholar Rock Holding Corp (NASDAQ:SRRK) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 ...

Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode. After the company’s prepared remarks all ...

Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) has been given a consensus rating of “Buy” by the seven brokerages ...

Wedbush reaffirmed their outperform rating on shares of Scholar Rock (NASDAQ:SRRK – Free Report) in a report published on Monday,RTT News reports. They currently have a $37.00 target price on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...